Article

Two-year data promising for dual-optic accommodating IOL

The newer generation of a dual-optic accommodating IOL (Synchrony, Visiogen) is easy to implant, centers well, provides good distance visual acuity, and demonstrates good safety in terms of potential posterior capsule opacification development, according to H. Burkhard Dick, MD.

The newer generation of a dual-optic accommodating IOL (Synchrony, Visiogen) is easy to implant, centers well, provides gooddistance visual acuity, and demonstrates good safety in terms of potential posterior capsule opacification development,according to H. Burkhard Dick, MD.

Dr. Dick, professor of ophthalmology, Johannes-Gutenberg University, Mainz, Germany, discussed 2-year data related to hisexperience of implanting 30 of the silicone lenses, which have a high diopter anterior optic and a minus power posterioroptic, in a prospective trial of otherwise healthy eyes.

"The most important thing was preoperative counseling and biometrics," he said. "This included lens thickness evaluation."

Focus curve measurement showed that the IOL demonstrated accommodative amplitude in every patient, even after 2 years, Dr.Dick said. The mean was 1.5 to 1.75 D. Also, he said, no Nd:YAG capsulotomies have been required.

"All patients were very satisfied with the lens, and in terms of functionality, it was quite satisfying. Also, reading speedwas very sufficient," Dr. Dick said.

Because of its relatively large size, the IOL requires a relatively large incision for implantation, he said.

"My standard incision size is about 2.75 mm, but this is a thickness [where] you can't implant this lens," Dr. Dick said.

The lens has earned a CE Mark in Europe, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.